Dyne Therapeutics, Inc.
DYNDyne Therapeutics is a clinical-stage biotechnology company focused on developing life-transforming therapies for people living with genetically driven neuromuscular diseases.
Earnings
Next report
Nov 4, 2026 (in 3 months)Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Dyne Therapeutics is a clinical-stage biotechnology company focused on developing life-transforming therapies for people living with genetically driven neuromuscular diseases. The company utilizes its proprietary FORCE platform to deliver targeted therapeutics, including oligonucleotides and enzymes, to muscle tissue and the central nervous system. Its core value proposition lies in overcoming delivery challenges to skeletal, cardiac, and smooth muscle to potentially stop or reverse disease progression.
Dyne is a clinical-stage innovator in the neuromuscular space, positioning its FORCE platform as a superior delivery mechanism compared to traditional naked oligonucleotides and viral gene therapies.
FAQ
- What is Dyne Therapeutics, Inc.'s market cap?
- Dyne Therapeutics, Inc. (DYN) has a market capitalization of $4.8B and trades on NASDAQ.
- Who are Dyne Therapeutics, Inc.'s competitors?
- Dyne Therapeutics, Inc.'s key competitors include Avidity Biosciences, Inc., Entrada Therapeutics, Inc., Wave Life Sciences Ltd., and others. These companies compete in similar markets and product categories.
- Who does Dyne Therapeutics, Inc. partner with?
- Dyne Therapeutics, Inc.'s notable partners include Avidity Biosciences, Inc., University of Mons, Sarepta Therapeutics, Inc., and others.
- Where is Dyne Therapeutics, Inc. headquartered?
- Dyne Therapeutics, Inc. is headquartered in United States of America and employs approximately 143 people. It has been publicly traded since 2020.